Effects of obesity on metabolic and cardiovascular outcomes following insulin initiation in patients with type 2 diabetes

Among patients with T2D insulin initiators, obesity adversely influences HbA1c up to 12 months, but not beyond 24 months and is associated with a decrease in BMI compared to non-obese groups. Morbidly obese patients initiating insulin have 30% increased risk of composite CV events after 5 years.